Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia Extends Biosimilar Education Efforts

GBMA-Led Biosimilar Education Program Will Now Run To June 2022

Executive Summary

Australia’s government has agreed to extend a successful biosimilar education initiative led by the local GBMA industry association.

You may also be interested in...



Australian Association Alleges Anti-Competitive Adalimumab Antics From AbbVie

AbbVie is spreading confusion among Australian doctors and patients with anti-competitive materials designed to fend off biosimilar adalimumab competition to Humira, according to a local biosimilars industry association.

Lupin Acquires Australia’s Southern Cross

Lupin has broadened its reach in Australia after agreeing a deal to buy local generics developer and distributor Southern Cross.

Amgen’s Bevacizumab Biosimilar Is Alone On Australia’s PBS

US-based giant Amgen has seen its Mvasi biosimilar become the sole bevacizumab product listed on Australia’s Pharmaceutical Benefits Scheme.

Related Content

Topics

UsernamePublicRestriction

Register

GB150896

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel